Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

InforSense Partners with U.K.’s Leading Institutions to Combat Alzheimer’s Disease

Published: Wednesday, December 03, 2008
Last Updated: Wednesday, December 03, 2008
Bookmark and Share
Translational research solution to help accelerate early diagnosis and personalized medicine treatments.

InforSense Ltd. has announced that the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service (NHS) Foundation Trust (SLaM) and Institute of Psychiatry, King’s College London will use InforSense’s translational research solutions in Alzheimer’s disease studies to advance the development of early diagnostic tools and develop personalized medicine treatments within mental health research.

For the first time, informaticians, researchers and clinicians will be able to directly access their entire patient and ‘omics’ data  through a common data analysis platform. The InforSense solution will eliminate errors associated with manual data processes and bottlenecks relating to data access and analysis by non specialist end users.

“Our research centers on understanding the molecular and cellular events that take place in the brain in Alzheimer’s disease and in particular we are working on blood based biomarkers to aid early diagnosis,” said Simon Lovestone, Professor of Old Age Psychiatry at King’s College London and Director of the Biomedical Research Centre for Mental Health.

“The translational solutions that InforSense provides will enable us to have an integrated data set under a common system that informaticians, researchers and clinicians can all use to access and analyze data. This will result in improved data sharing and removal of access bottlenecks, speeding up the speed and accuracy of novel biomarker identification.”

Translational research is the practice of linking clinical and research data to identify early diagnostics, also known as biomarkers, improve disease understanding and ultimately enhance patient care.

The InforSense Translational Research solution, including the InforSense platform, ClinicalSense, GenSense, and BioSense, will be used by the Biomedical Research Centre for Mental Health to integrate and analyze patient, genotyping, transcriptomics, proteomics and MRI data to support the identification of biomarkers. Researchers will also be able to access and analyze data using the VisualSense interactive web portal.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InforSense GenSense Achieves GeneChip-compatible™ Status with the Affymetrix GeneChip® Microarray Platform
Affymetrix has become a member of InforSense’s Open Workflow Partner Network joining over 40 other partners in the program.
Tuesday, August 07, 2007
InforSense® Announces Conference Series
The InforSense Users Conference will provide opportunity to learn how InforSense KDE is being used to facilitate business-critical decision-making across a variety of industries.
Tuesday, November 14, 2006
$10 Million Investment to Boost InforSense Expansion
Fleming Family & Partners Private Equity and Imperial Innovations lead strategic investment round.
Tuesday, October 10, 2006
EU-Funded ARGUGRID Project Adopts InforSense® Integrative Analytics Technology
InforSense to provide integrative analytics environment to support collaborative decision making.
Wednesday, October 04, 2006
InforSense® Appoints David Hadfield as Chief Operating Officer
Former Spotfire executive strengthens InforSense management team.
Tuesday, October 03, 2006
Bayer Selects InforSense for Next Generation Integrative Analytics Infrastructure
InforSense KDE, will provide Bayer with a flexible rapid application development platform to optimize their drug discovery decision-making.
Friday, September 16, 2005
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos